Dr Jerome Rossert (Head of Clinical Renal, AstraZeneca) joins us to discuss the findings of IMPACT CKD, a modelling analysis study aiming to evaluate the potential impact of chronic kidney disease across the next 10 years.

IMPACT CKD included eight countries, the United States, Brazil, the United Kingdom, Spain, Germany, the Netherlands, China and Australia. The findings of the study estimate that almost 125 million people will suffer from advanced CKD by 2032, whilst the economic toll of renal replacement therapy will cost $186 billion. Dialysis treatments will increase by over 75%, significantly increasing the carbon footprint of healthcare in CO2 emissions.

Interview Questions:

1. What is the IMPACT-CKD Study?
2. What should be the impact on practice?
3. What steps can be taken by clinicians to prevent these outcomes?
4. What should be the impact of these findings on healthcare policies?

Recorded Remotely from Sweden, 2024.

Interviewer: Jordan Rance
Video Specialists: Oliver Miles